Buscar
Atara Biotherapeutics Inc
ATRAAñadir a la lista de seguimiento
8.380USD
+0.210+2.57%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
75.51MCap. mercado
PérdidaP/E TTM
Más Datos de Atara Biotherapeutics Inc Compañía
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Información de Atara Biotherapeutics Inc
Símbolo de cotizaciónATRA
Nombre de la empresaAtara Biotherapeutics Inc
Fecha de salida a bolsaOct 16, 2014
Director ejecutivoNguyen (Anhco)
Número de empleados153
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 16
Dirección1280 Rancho Conejo Blvd
CiudadTHOUSAND OAKS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91320
Teléfono18056234211
Sitio Webhttps://www.atarabio.com/
Símbolo de cotizaciónATRA
Fecha de salida a bolsaOct 16, 2014
Director ejecutivoNguyen (Anhco)
Ejecutivos de Atara Biotherapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. James Huang
Mr. James Huang
Independent Director
Independent Director
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Atara Biotherapeutics Inc?
Los cinco principales accionistas de Atara Biotherapeutics Inc son: Mr. William K. Heiden
¿Cuántas instituciones poseen acciones de Atara Biotherapeutics Inc (ATRA)?
A fecha de 2026Q1, 156 instituciones poseen acciones de Atara Biotherapeutics Inc, con un valor de mercado combinado de aproximadamente 3.70M, lo que representa el 43.48% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -645280.00.